Company news
CRISPR Therapeutics AG news in 2020
CRISPR Therapeutics AG's news releases, calls and decks from 2020, newest first.
CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV
December 13, 2020
CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine
December 4, 2020
CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 23, 2020
CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
November 15, 2020
CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition
November 3, 2020
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results
October 27, 2020
CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies
October 20, 2020
CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry
October 6, 2020
CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease
September 21, 2020
CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference
September 2, 2020
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results
July 26, 2020
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
June 29, 2020
CRISPR Therapeutics Announces Proposed Offering of Common Shares
June 28, 2020
CRISPR Therapeutics Announces the Build-Out of New Cell Therapy Manufacturing Facility
June 24, 2020
CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress
June 11, 2020
CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting
May 14, 2020
New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress
May 13, 2020
CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies
May 10, 2020
CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference
May 6, 2020
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results
April 27, 2020
CRISPR Therapeutics Proposes Changes to the Board of Directors
February 25, 2020
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
February 11, 2020
CRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference
January 5, 2020
Decks in 2020
- 62nd Annual American Society of Hematology Meeting (December 2020)
Conference · 18 slides · Dec 7, 2020
- Technical Presentation (October 2020)
Technical · 22 slides · Oct 21, 2020
- 25th Congress of the European Hematology Association (Virtual Edition) (June 2020)
Conference · 21 slides · Jun 12, 2020